e-learning
resources
Barcelona 2010
Sunday, 19.09.2010
Experimental pulmonary hypertension
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Two rat models of hemolysis-induced pulmonary hypertension
V. Bilan, S. Tofovic (United States Of America)
Source:
Annual Congress 2010 - Experimental pulmonary hypertension
Session:
Experimental pulmonary hypertension
Session type:
Thematic Poster Session
Number:
1071
Disease area:
Pulmonary vascular diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
V. Bilan, S. Tofovic (United States Of America). Two rat models of hemolysis-induced pulmonary hypertension. Eur Respir J 2010; 36: Suppl. 54, 1071
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
From pulmonary gas exchange to the interpretation of arterial blood gases
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Related content which might interest you:
Pirfenidone protects against pulmonary hypertension in the Sugen5416/hypoxia rat model
Source: International Congress 2018 – Risk stratification in treatment of pulmonary arterial hypertension
Year: 2018
Reversibility of the monocrotaline pulmonary hypertension rat model
Source: Eur Respir J 2013; 42: 553-556
Year: 2013
A novel murine model of severe pulmonary arterial hypertension
Source: Annual Congress 2010 - Experimental pulmonary hypertension
Year: 2010
R-Crizotinib predisposes to and exacerbates pulmonary arterial hypertension in animal models
Source: Eur Respir J, 57 (5) 2003271; 10.1183/13993003.03271-2020
Year: 2021
Inflammatory changes in a murine model of monocrotaline-induced pulmonary hypertension
Source: Eur Respir J 2005; 26: Suppl. 49, 365s
Year: 2005
Regulation of connexins by hypoxia in rat pulmonary vascular cells in an in vitro model of pulmonary hypertension
Source: International Congress 2017 – Experimental PH
Year: 2017
Zamicastat decreases cardiac arrhythmias in a rat model of pulmonary arterial hypertension
Source: Virtual Congress 2020 – Experimental approaches to pulmonary hypertension
Year: 2020
Renal denervation reduces pulmonary vascular remodeling in two experimental pulmonary arterial hypertension models
Source: International Congress 2015 – Pulmonary hypertension: new treatment insights
Year: 2015
SuHx rat model: partly reversible pulmonary hypertension and progressive intima obstruction
Source: Eur Respir J 2014; 44: 160-168
Year: 2014
Bevacizumab administration in monocrotaline induced pulmonary arterial hypertension rat model
Source: Annual Congress 2010 - Pulmonary vascular diseases
Year: 2010
Bevacizumab administration in pulmonary arterial hypertension rat model decondary to chronical hypoxia exposure
Source: Annual Congress 2010 - Experimental pulmonary hypertension
Year: 2010
Caspase inhibition reduces severe pulmonary hypertension in the AdTGF-1β/SU5416 model of angioproliferative pulmonary hypertension and lung fibrosis
Source: Annual Congress 2011 - Experimental pulmonary hypertension
Year: 2011
An investigation of the origins of pulmonary artery lesion cells in pulmonary arterial hypertension rat models
Source: International Congress 2019 – Pulmonary hypertension: novelties from the bench
Year: 2019
Terguride ameliorates monocrotaline-induced pulmonary hypertension in rats
Source: Eur Respir J 2011; 37: 1104-1118
Year: 2011
MnTBAP reduces pulmonary vascular remodeling in experimental pulmonary arterial hypertension
Source: International Congress 2019 – Pulmonary hypertension: novelties from the bench
Year: 2019
Improvement of exercise capacity in monocrotaline induced pulmonary hypertension by the phosphodiesterase inhibitor Vardenafil
Source: Annual Congress 2006 - Signalisation in the pulmonary vasculature: new pathways and wrong signals
Year: 2006
Vascular reverse remodeling in the mouse model of hypoxia-induced pulmonary hypertension
Source: Annual Congress 2010 - Experimental pulmonary hypertension
Year: 2010
ACE2 activation improves pulmonary endothelial function and attenuates monocrotaline-induced pulmonary hypertension
Source: Annual Congress 2011 - Treatment of human pulmonary hypertension
Year: 2011
Formation of typical vascular lesions in a new experimental model of pulmonary arterial hypertension
Source: Annual Congress 2013 –Pulmonary circulation: animal models and experimental treatments
Year: 2013
Reversal of pulmonary hypertension in a sugen/hypoxic rat model using an ASK1 inhibitor
Source: International Congress 2017 – New perspectives from experimental models of pulmonary hypertension
Year: 2017
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept